Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking

Vernette J. Molloy

Vernette J. Molloy, MBA, RN, is vice president of GCPA, Inc., Fairfax Station, Virginia.

Articles by Vernette J. Molloy

A Closer Look at 1572: Interpreting the FDA's Statement of Investigator Form

ByMark P. Mathieu,Vernette J. Molloy,Douglas R. Mackintosh

September 1st 2010

Applied Clinical Trials Supplements

A new reference guide clarifies uncertainty surrounding this sometimes misunderstood document.

A Closer Look at the 1572: Interpreting the FDA's Statement of Investigator Form

ByMark P. Mathieu,Vernette J. Molloy,Douglas R. Mackintosh

October 1st 2004

Applied Clinical Trials

A new reference guide clarifies uncertainty surrounding this sometimes misunderstood document.

Latest Updated Articles

A Closer Look at 1572: Interpreting the FDA's Statement of Investigator Form
September 1st 2010
A Closer Look at the 1572: Interpreting the FDA's Statement of Investigator Form
October 1st 2004

Trending on Applied Clinical Trials Online

When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny

ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy

Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development

How AI Is Changing Endpoint Selection Before a Trial Even Starts

Trust, Technology, and the Patient-Site Relationship: Q&A with Andrea Valente, uMotif